Navigation Links
Warner Chilcott Successfully Completes Refinancing of Senior Secured Credit Facilities and Updates Full Year 2011 Financial Guidance
Date:3/17/2011

costs for the balance of 2011.  Full year 2011 CNI, as defined above, is now expected to increase by $0.15 per share from a range of $3.45 to $3.55 per share, to a range of $3.60 to $3.70 per share.  The anticipated increase in CNI per share is attributable to the decrease in the Company's 2011 after-tax cash interest expense resulting from the refinancing, offset, in part, by certain fees and expenses associated with the refinancing. The expected impact on CNI per share is based on 256 million fully-diluted shares outstanding.  Please refer to the attached exhibit for full details of the Company's 2011 revised financial guidance.  

The Company Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare, gastroenterology, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-F

Forward Looking Statements This press release contains forward-looking statements, including statements concerning our operations, our anticipated financial performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reason
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive
2. Warner Chilcott Announces 2011 Financial Guidance Conference Call
3. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
4. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
5. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
6. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
7. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
8. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
9. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
10. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
11. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. ... phosphorous through the activities in the soil or in ... to the stress on reducing environmental pollution and on ... defines and segments the bio fertilizers market with analysis ...
(Date:1/22/2015)... Shimadzu Scientific Instruments today announces ... spectrophotometer. Offering wavelength scanning from 190 to 1,100 ... applications in a variety of industries, including environmental, ... UV-1280 enables intuitive operation, while the enhanced validation, ...
(Date:1/22/2015)... (PRWEB) January 21, 2015 Cambridge Semantics, the ... technology, today announced that 2014 was a record-breaking year across ... capabilities of the Anzo Smart Data Platform and our Smart ... utilize insights from diverse data which led to record growth ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... Computing Workstations with Unique Integration ... Patients, COLUMBUS, Ohio, Feb. 26 ... healthcare technology solutions for the,long-term and acute ... with McKesson Automation, Inc., a division of ...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) today reported financial ... 2007., For the quarter ended December 31, 2007, the ... share. This compares to a net loss of,$68.1 million, or ... $34.2,million, or $0.58 per share, for the prior quarter ended ...
... BioSpace, the world,s leading,online bioscience job board community ... biotechnology and pharmaceutical job seekers to the,Genetown Career ... Thirty-six bioscience companies exhibited at the event ... as well as the,quantity of the candidates. "The ...
Cached Biology Technology:Artromick Aligns with McKesson to Enhance Medication Safety at the Patient's Bedside 2Artromick Aligns with McKesson to Enhance Medication Safety at the Patient's Bedside 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 8BioSpace Boston Career Fair Attracts over 900 Bioscience Candidates 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ...  report to their offering. One major ... With continuous advances in technology, it is important to ...
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced plans ... Medicine. Funding for this $50 million capital project is part ... next summer. The medical education building will ... Company complex, adjacent to 525@vine in Wake Forest Innovation Quarter. ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... showing off the powers of new high-resolution 3-D imaging, ... sorts newly synthesized proteins for transport inside and outside ... according to research to be presented on Sunday, Dec. ... annual meeting in New Orleans. With conventional microscopy ...
... the outstanding work of five young researchers from China, ... IOF Young Investigator Awards, valued at 1,000 USD each, ... to the 4th Asia-Pacific Osteoporosis Meeting by researchers under ... at the Hong Kong Convention and Exhibition Centre, is ...
... level of DNA -- one amino acid on one gene -- ... different amino acid on the same gene in your friend,s body ... at Duke University. There are about 400 genes coding for ... Project, there are more than 900,000 variations of those genes. These ...
Cached Biology News:High-resolution 3-D imaging draws new picture of Golgi's whereabouts during cell division 2Young investigators awarded for research excellence at Hong Kong meeting 2No 2 people smell the same 2
... anti-phospho-FAK (Ser843) ... acid region encompassing the human, mouse, ... Accession Number: NM_153831 ... Routinely evaluated by immunoblot. ...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: